Lv75
3770 积分 2021-10-11 加入
High time for risk-adapted treatment in mantle cell lymphoma
37分钟前
待确认
5-y Follow-up of Combination of Ibrutinib, Obinutuzumab and Venetoclax for Patients with Newly Diagnosed Mantle Cell Lymphoma, the Oasis Trial
2小时前
已关闭
Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial
9小时前
已完结
Single-cell sequencing in diffuse large B-cell lymphoma: C1qC is a potential tumor-promoting factor
1天前
已完结
Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18–65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network
2天前
已完结
Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in TP53 -Mutated Diffuse Large B-Cell Lymphoma
3天前
已完结
Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN
3天前
已完结
Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
3天前
已完结
Does TRIANGLE take down transplantation in mantle cell lymphoma?
5天前
已完结
The preclinical discovery and development of acalabrutinib for the treatment of mantle cell lymphoma
9天前
已完结
皖公网安备34019202002308
